Lacosamide

證據等級: L5

預測適應症: 10 個

Lacosamide: From Epilepsy to Manic Bipolar Affective Disorder

One-Sentence Summary

Lacosamide is an antiepileptic drug (AED), acting as a sodium-channel modulator used for partial-onset seizures. The TxGNN model predicts it may be effective for manic bipolar affective disorder, but the strongest current evidence (1 recruiting Phase 3 trial and multiple retrospective/case reports) addresses bipolar depressive, not manic, episodes — a polarity mismatch that limits confidence in this specific prediction.

Note: original_indications and original_moa were not populated in the evidence pack (data gap DG002). "Epilepsy (partial-onset seizures)" is inferred from the supporting literature/trial descriptions (e.g., "FDA-approved for treating partial seizures," "adjunctive treatment for partial epilepsy"), not from a formal indication field.

Quick Overview

Item	Content
Original Indication	Epilepsy (partial-onset seizures) — inferred from literature, not a formal labeled field
Predicted New Indication	Manic bipolar affective disorder
TxGNN Prediction Score	99.96% (rank 711)
Evidence Level	L3
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Research Question (Hold pending confirmatory data)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002). Based on known information, lacosamide selectively enhances slow inactivation of voltage-gated sodium channels — a mechanism pharmacologically related to established mood stabilizers such as lamotrigine, which is used clinically for bipolar disorder. This shared class-level mechanism is the biological rationale behind the TxGNN prediction.

However, the relationship between the original indication (epilepsy) and the predicted new indication (bipolar mania) is indirect. Existing clinical and case-level evidence on lacosamide in bipolar disorder consistently centers on depressive and mixed/anxious symptoms — e.g., open-label improvement of depressive symptoms, and the only ongoing Phase 3 trial (NCT07412132) specifically targets major depressive episodes in Bipolar I/II. No trial or publication in this evidence pack directly demonstrates antimanic efficacy, so the mechanistic story (sodium-channel stabilization → mood stabilization) is plausible but has not been shown to extend to the manic pole specifically.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07412132	Phase 3	Recruiting	40	Evaluates lacosamide as augmentation therapy for major depressive episodes in Bipolar I/II (not mania); based on prior observational/open-label signals of mood improvement in epilepsy and bipolar patients. Polarity mismatch with the "manic" prediction — no results yet.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30251375	2018	Retrospective cohort	Psychiatry Clin Neurosci	30-day comparison of lacosamide vs. other AEDs in bipolar disorder patients without epilepsy — first dedicated look at lacosamide in BD.
33666402	2021	Open-label pilot	J Clin Psychopharmacol	12-week open-label pilot showing efficacy/safety signal specifically in bipolar depression.
29253680	2018	Prospective multicenter	Epilepsy Behav	Lacosamide associated with improved depression/anxiety symptoms in focal epilepsy patients — precursor signal for psychiatric use.
28845834	2017	Case report	Acta Biomed	Mood stabilization achieved with lacosamide in a patient with comorbid mood disorder, PTSD, and fronto-temporal epilepsy.
30275630	2018	Case report (adverse event)	Indian J Psychol Med	Neutropenia precipitated by lacosamide in a patient with bipolar disorder and comorbid epilepsy — safety signal.
38304661	2024	Case report	Cureus	Complex case of Bipolar I disorder with multiple comorbidities including seizure-like activity; illustrative rather than efficacy evidence.
29957667	2018	Review	Ther Drug Monit	Notes AEDs, including lacosamide's class, are used off-label in bipolar disorder management.
22210279	2012	Review	Adv Drug Deliv Rev	Background on lacosamide's chemical/pharmacokinetic properties among newer AEDs.
32693579	2020	Review	ACS Chem Neurosci	Discusses CRMP2 as a druggable target relevant to lacosamide's mechanism of action.
37782796	2023	Mechanistic	PNAS	Cryo-EM structural mechanism of Nav channel inhibition by lamotrigine, a related mood-stabilizing AED — supports the shared-mechanism rationale.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data were not available in this evidence pack — DG001, classified as Blocking, prevents a full S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Research Question (Hold pending confirmatory data)

Rationale: The mechanistic rationale (sodium-channel slow-inactivation, class analogy to lamotrigine) is plausible, but all available clinical evidence for lacosamide in bipolar disorder addresses the depressive pole (open-label pilot, retrospective cohort, one recruiting Phase 3 trial), not the manic pole predicted here — a direct polarity mismatch flagged in the evidence pack's own relevance grading (Grade B). No completed trial or literature currently supports antimanic efficacy.

To proceed, the following is needed:

TFDA/EMA package insert data to close the Blocking safety gap (DG001) before any S1 progression
Formal MOA documentation (DG002) to substantiate the sodium-channel-to-mood-stabilization mechanistic link
Results from NCT07412132 (depressive-episode trial) once available, to gauge translatability to manic presentations
Consider re-scoping the candidate indication toward "bipolar depression" specifically, where evidence is materially stronger than for "manic bipolar affective disorder"
Note: within this same evidence pack, migraine disorder (rank 5) shows substantially stronger evidence (L1, head-to-head Phase 3 RCTs vs. propranolol, decision stage S3, "Proceed with Guardrails") and may warrant separate, higher-priority evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.